RCUS — Arcus Biosciences Share News
0.000.00%
Last trade - 00:00- $2.91bn
- $2.30bn
- $247.00m
U.S. STOCKS ON THE MOVE-Marathon Petroleum, Five Below, GM
U.S. STOCKS ON THE MOVE-Super Micro Computer, Arcus Biosciences, Agape ATP
Arcus Biosciences surges after Gilead Sciences raises stake
Arcus Biosciences rises after Gilead raises stake to 33%
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
Brief: Gilead Sciences Inc Amendment Provides Gilead With One Additional Seat On Arcus Board
Brief: Arcus Biosciences Says Data From Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
Brief: Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Zanzalintinib In Combination With Ab521
Brief: Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Advanced Renal Cell Carcinoma Drug
Brief: Arcus Biosciences Q3 revenue USD 32 million vs. IBES estimate USD 27.3 million
Brief: Gilead And Arcus Announce New Data Showing Encouraging Clinical Activity Of Anti-TIGIT Domvanalimab-Containing Regimen As First-Line Treatment For Upper GI Cancers
Arcus Biosciences Inc expected to post a loss of $1.13 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Netflix, AMC Entertainment, Nike
U.S. STOCKS ON THE MOVE-Toll Brothers, AMC Entertainment, Peloton Interactive
Cancer drugmakers gain after Roche discloses positive data from drug study
U.S. STOCKS ON THE MOVE-Thermo Fisher Scientific, Heliogen, Foot Locker
U.S. STOCKS ON THE MOVE-Manchester United, Apellis Pharma, cancer drugmakers
Cancer drugmakers gain after Roche discloses positive data from drug study
Arcus Biosciences Inc reports results for the quarter ended in June - Earnings Summary